A Harvard study suggests when the FDA rushes drugs to market, safety may be overlooked
Those drugs are more likely to be recalled or re-labeled.
A 1992 law gave the fda 12 months to review most new drug applications.
That was later revised to 10 months -- and just six for drugs on a fast-track.
Researchers found drugs approved just before deadline were more than five times likely to be pulled off the market.
That same law requires drug companies to pay half the fda's budget for drug approvals.
The FDA says it did its own review and found no problems with drugs approved before, near or after deadline.
But, both agencies agree that the FDA needs more people and money to meet those deadlines and ensure safety.
